PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29695399-3	2018	The present study analyzed the influence of well-established tyrosine kinase inhibitors nilotinib, dasatinib, erlotinib and gefitinib on the expression of HIF-1alpha and mTOR in p16-positive and -negative squamous cancer cells (SCC) in vitro in order to develop novel strategies in the treatment of HNSCC.	Erlotinib Hydrochloride	110-119	cyclin dependent kinase inhibitor 2A	Homo sapiens	178-181	
28521433-7	2017	VEGFR-1 expression was significantly increased in p16-positive SCC cells following treatment with nilotinib, dasatinib, erlotinib and gefitinib (P<0.05).	Erlotinib Hydrochloride	120-129	cyclin dependent kinase inhibitor 2A	Homo sapiens	50-53